Spectrum of Restrictive and Infiltrative Cardiomyopathies: Part 2 of a 2-Part Series

Journal of the American College of Cardiology

Volumn 71, Issue 10, 2018, Pages 1149-1166

  Pereira, Naveen L ^a   Grogan, Martha ^a   Dec, G William ^b  

^a MAYO CLINIC   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

heart failure; restrictive cardiomyopathy; sarcoidosis

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; ALPHA INTERFERON; AMLODIPINE; ANTICOAGULANT AGENT; ANTIOXIDANT; AZATHIOPRINE; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DIURETIC AGENT; HYDROXYUREA; INFLIXIMAB; METHOTREXATE; MYCOPHENOLATE MOFETIL; PREDNISONE; RITUXIMAB; TAURINE;

ANTIOXIDANT ACTIVITY; CARDIAC SARCOIDOSIS; CARDIOMYOPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL FEATURE; CONTINUOUS INFUSION; DIET THERAPY; ECHOCARDIOGRAPHY; ENDOCARDIAL FIBROELASTOSIS; HEART AMYLOIDOSIS; HEART ARRHYTHMIA; HEART BLOCK; HEART DISEASE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART MUSCLE BIOPSY; HEART MUSCLE FIBROSIS; HEART VALVE REPLACEMENT; HEMOCHROMATOSIS; HUMAN; HYPEREOSINOPHILIC SYNDROME; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFILTRATIVE CARDIOMYOPATHY; IRON CHELATION; IRON OVERLOAD; IRON OVERLOAD CARDIOMYOPATHY; NONHUMAN; PHLEBOTOMY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RADIATION INDUCED HEART DISEASE; RADIATION INJURY; RESTRICTIVE CARDIOMYOPATHY; REVIEW; SODIUM RESTRICTION;

EID: 85042257964     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2018.01.017     Document Type: Review

References (182)

1. Elliott, P., Andersson, B., Arbustini, E., et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 29 (2008), 270–276.
2. Kushwaha, S.S., Fallon, J.T., Fuster, V., Restrictive cardiomyopathy. N Engl J Med 336 (1997), 267–276.
3. Bhattacharyya, S., Davar, J., Dreyfus, G., Caplin, M.E., Carcinoid heart disease. Circulation 116 (2007), 2860–2865.
4. Grimaldi, A., Mocumbi, A.O., Freers, J., et al. Tropical endomyocardial fibrosis: natural history, challenges, and perspectives. Circulation 133 (2016), 2503–2515.
5. Mocumbi, A.O., Ferreira, M.B., Sidi, D., Yacoub, M.H., A population study of endomyocardial fibrosis in a rural area of Mozambique. N Engl J Med 359 (2008), 43–49.
6. Mocumbi, A.O., Yacoub, S., Yacoub, M.H., Neglected tropical cardiomyopathies: II. Endomyocardial fibrosis: myocardial disease. Heart 94 (2008), 384–390.
7. Mocumbi, A.O., Latif, N., Yacoub, M.H., Presence of circulating anti-myosin antibodies in endomyocardial fibrosis. PLoS Negl Trop Dis, 4, 2010, e661.
8. Mathai, A., Kartha, C.C., Balakrishnan, K.G., Serum immunoglobulins in patients with endomyocardial fibrosis. Indian Heart J 38 (1986), 470–472.
9. Andy, J.J., Ogunowo, P.O., Akpan, N.A., Odigwe, C.O., Ekanem, I.A., Esin, R.A., Helminth associated hypereosinophilia and tropical endomyocardial fibrosis (EMF) in Nigeria. Acta Trop 69 (1998), 127–140.
10. Teles, F.F., Chronic poisoning by hydrogen cyanide in cassava and its prevention in Africa and Latin America. Food Nutr Bull 23 (2002), 407–412.
11. Tharakan, J., Bohora, S., Current perspective on endomyocardial fibrosis. Curr Sci 97 (2009), 405–410.
12. Freers, J., Mayanja-Kizza, H., Rutakingirwa, M., Gerwing, E., Endomyocardial fibrosis: why is there striking ascites with little or no peripheral oedema?. Lancet, 347, 1996, 197.
13. Desser, K.B., Ascites in tropical endomyocardial fibrosis. Clin Cardiol, 30, 2007, 634 author reply 634.
14. Tharakan, J.A., Electrocardiogram in endomyocardial fibrosis. Indian Pacing Electrophysiol J 11 (2011), 129–133.
15. Shaper, A.G., Wright, D.H., Intracardiac thrombosis and embolism in endomyocardial fibrosis in Uganda. Br Heart J 25 (1963), 502–508.
16. Berensztein, C.S., Pineiro, D., Marcotegui, M., Brunoldi, R., Blanco, M.V., Lerman, J., Usefulness of echocardiography and doppler echocardiography in endomyocardial fibrosis. J Am Soc Echocardiogr 13 (2000), 385–392.
17. Hassan, W.M., Fawzy, M.E., Al Helaly, S., Hegazy, H., Malik, S., Pitfalls in diagnosis and clinical, echocardiographic, and hemodynamic findings in endomyocardial fibrosis: a 25-year experience. Chest 128 (2005), 3985–3992.
18. Leon, D., Martin, M., Corros, C., Santamarta, E., Costilla, S., Lambert, J.L., Usefulness of CMR in the early diagnosis of endomyocardial fibrosis. Rev Port Cardiol 31 (2012), 401–402.
19. Schneider, U., Jenni, R., Turina, J., Turina, M., Hess, O.M., Long-term follow up of patients with endomyocardial fibrosis: effects of surgery. Heart 79 (1998), 362–367.
20. Joshi, R., Abraham, S., Kumar, A.S., New approach for complete endocardiectomy in left ventricular endomyocardial fibrosis. J Thorac Cardiovasc Surg 125 (2003), 40–42.
21. Ino, T., Benson, L.N., Freedom, R.M., Rowe, R.D., Natural history and prognostic risk factors in endocardial fibroelastosis. Am J Cardiol 62 (1988), 431–434.
22. Fathi, A.T., Dec, G.W. Jr., Richter, J.M., et al. Case records of the Massachusetts General Hospital. Case 7-2014. A 27-year-old man with diarrhea, fatigue, and eosinophilia. N Engl J Med 370 (2014), 861–872.
23. Crane, M.M., Chang, C.M., Kobayashi, M.G., Weller, P.F., Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence. J Allergy Clin Immunol 126 (2010), 179–181.
24. Weller, P.F., Bubley, G.J., The idiopathic hypereosinophilic syndrome. Blood 83 (1994), 2759–2779.
25. Cheah, C.Y., Burbury, K., Apperley, J.F., et al. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood 123 (2014), 3574–3577.
26. Ommen, S.R., Seward, J.B., Tajik, A.J., Clinical and echocardiographic features of hypereosinophilic syndromes. Am J Cardiol 86 (2000), 110–113.
27. Srichai, M.B., Junor, C., Rodriguez, L.L., et al. Clinical, imaging, and pathological characteristics of left ventricular thrombus: a comparison of contrast-enhanced magnetic resonance imaging, transthoracic echocardiography, and transesophageal echocardiography with surgical or pathological validation. Am Heart J 152 (2006), 75–84.
28. Syed, I.S., Martinez, M.W., Feng, D.L., Glockner, J.F., Cardiac magnetic resonance imaging of eosinophilic endomyocardial disease. Int J Cardiol 126 (2008), e50–e52.
29. Moosbauer, C., Morgenstern, E., Cuvelier, S.L., et al. Eosinophils are a major intravascular location for tissue factor storage and exposure. Blood 109 (2007), 995–1002.
30. Ogbogu, P.U., Bochner, B.S., Butterfield, J.H., et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 124 (2009), 1319–1325.e3.
31. Butterfield, J.H., Weiler, C.R., Treatment of hypereosinophilic syndromes—the first 100 years. Semin Hematol 49 (2012), 182–191.
32. Boustany, C.W. Jr., Murphy, G.W., Hicks, G.L. Jr., Mitral valve replacement in idiopathic hypereosinophilic syndrome. Ann Thorac Surg 51 (1991), 1007–1009.
33. Murphy, C.J., Oudit, G.Y., Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment. J Card Fail 16 (2010), 888–900.
34. Gujja, P., Rosing, D.R., Tripodi, D.J., Shizukuda, Y., Iron overload cardiomyopathy: betterunderstanding of an increasing disorder. J Am Coll Cardiol 56 (2010), 1001–1012.
35. Kremastinos, D.T., Farmakis, D., Iron overload cardiomyopathy in clinical practice. Circulation 124 (2011), 2253–2263.
36. Andrews, N.C., Disorders of iron metabolism. N Engl J Med 341 (1999), 1986–1995.
37. Eaton, J.W., Qian, M., Molecular bases of cellular iron toxicity. Free Radic Biol Med 32 (2002), 833–840.
38. Oudit, G.Y., Sun, H., Trivieri, M.G., et al. L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med 9 (2003), 1187–1194.
39. Tsushima, R.G., Wickenden, A.D., Bouchard, R.A., Oudit, G.Y., Liu, P.P., Backx, P.H., Modulation of iron uptake in heart by L-type Ca2+ channel modifiers: possible implications in iron overload. Circ Res 84 (1999), 1302–1309.
40. Kremastinos, D.T., Tsiapras, D.P., Tsetsos, G.A., Rentoukas, E.I., Vretou, H.P., Toutouzas, P.K., Left ventricular diastolic Doppler characteristics in beta-thalassemia major. Circulation 88 (1993), 1127–1135.
41. Liu, P., Olivieri, N., Iron overload cardiomyopathies: new insights into an old disease. Cardiovasc Drugs Ther 8 (1994), 101–110.
42. Olivieri, N.F., Nathan, D.G., MacMillan, J.H., et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 331 (1994), 574–578.
43. Brittenham, G.M., Griffith, P.M., Nienhuis, A.W., et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 331 (1994), 567–573.
44. Spirito, P., Lupi, G., Melevendi, C., Vecchio, C., Restrictive diastolic abnormalities identified by Doppler echocardiography in patients with thalassemia major. Circulation 82 (1990), 88–94.
45. Lubitz, S.A., Goldbarg, S.H., Mehta, D., Sudden cardiac death in infiltrative cardiomyopathies: sarcoidosis, scleroderma, amyloidosis, hemachromatosis. Prog Cardiovasc Dis 51 (2008), 58–73.
46. Palka, P., Macdonald, G., Lange, A., Burstow, D.J., The role of Doppler left ventricular filling indexes and Doppler tissue echocardiography in the assessment of cardiac involvement in hereditary hemochromatosis. J Am Soc Echocardiogr 15 (2002), 884–890.
47. Kremastinos, D.T., Tsiapras, D.P., Kostopoulou, A.G., Hamodraka, E.S., Chaidaroglou, A.S., Kapsali, E.D., NT-proBNP levels and diastolic dysfunction in beta-thalassaemia major patients. Eur J Heart Fail 9 (2007), 531–536.
48. Kremastinos, D.T., Hamodraka, E., Parissis, J., Tsiapras, D., Dima, K., Maisel, A., Predictive value of B-type natriuretic peptides in detecting latent left ventricular diastolic dysfunction in beta-thalassemia major. Am Heart J 159 (2010), 68–74.
49. Kremastinos, D.T., Heart failure in beta-thalassemia. Congest Heart Fail 7 (2001), 312–314.
50. Qaseem, A., Aronson, M., Fitterman, N., Snow, V., Weiss, K.B., Owens, D.K., Screening for hereditary hemochromatosis: a clinical practice guideline from the American College of Physicians. Ann Intern Med 143 (2005), 517–521.
51. Beutler, E., Felitti, V., Gelbart, T., Ho, N., The effect of HFE genotypes on measurements of iron overload in patients attending a health appraisal clinic. Ann Intern Med 133 (2000), 329–337.
52. Machado, R.F., Anthi, A., Steinberg, M.H., et al. N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. JAMA 296 (2006), 310–318.
53. Isma'eel, H., Chafic, A.H., El Rassi, F., et al. Relation between iron-overload indices, cardiac echo-Doppler, and biochemical markers in thalassemia intermedia. Am J Cardiol 102 (2008), 363–367.
54. Kremastinos, D.T., Farmakis, D., Aessopos, A., et al. Beta-thalassemia cardiomyopathy: history, present considerations, and future perspectives. Circ Heart Fail 3 (2010), 451–458.
55. Hamdy, A.M., Use of strain and tissue velocity imaging for early detection of regional myocardial dysfunction in patients with beta thalassemia. Eur J Echocardiogr 8 (2007), 102–109.
56. Palka, P., Lange, A., Atherton, J., Stafford, W.J., Burstow, D.J., Biventricular diastolic behaviour in patients with hypertrophic and hereditary hemochromatosis cardiomyopathies. Eur J Echocardiogr 5 (2004), 356–366.
57. Shizukuda, Y., Bolan, C.D., Tripodi, D.J., et al. Significance of left atrial contractile function in asymptomatic subjects with hereditary hemochromatosis. Am J Cardiol 98 (2006), 954–959.
58. Abraham, T.P., Dimaano, V.L., Liang, H.Y., Role of tissue Doppler and strain echocardiography in current clinical practice. Circulation 116 (2007), 2597–2609.
59. Shizukuda, Y., Bolan, C.D., Tripodi, D.J., et al. Does oxidative stress modulate left ventricular diastolic function in asymptomatic subjects with hereditary hemochromatosis?. Echocardiography 26 (2009), 1153–1158.
60. Cheng, H., Zhao, S., Jiang, S., et al. The relative atrial volume ratio and late gadolinium enhancement provide additive information to differentiate constrictive pericarditis from restrictive cardiomyopathy. J Cardiovasc Magn Reson, 13, 2011, 15.
61. Anderson, L.J., Holden, S., Davis, B., et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 22 (2001), 2171–2179.
62. Kondur, A.K., Li, T., Vaitkevicius, P., Afonso, L., Quantification of myocardial iron overload by cardiovascular magnetic resonance imaging T2* and review of the literature. Clin Cardiol 32 (2009), E55–E59.
63. Kirk, P., Roughton, M., Porter, J.B., et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 120 (2009), 1961–1968.
64. Wood, J.C., History and current impact of cardiac magnetic resonance imaging on the management of iron overload. Circulation 120 (2009), 1937–1939.
65. Reichek, N., MRI myocardial tagging. J Magn Reson Imaging 10 (1999), 609–616.
66. Aletras, A.H., Ingkanisorn, W.P., Mancini, C., Arai, A.E., DENSE with SENSE. J Magn Reson 176 (2005), 99–106.
67. Barosi, G., Arbustini, E., Gavazzi, A., Grasso, M., Pucci, A., Myocardial iron grading by endomyocardial biopsy. A clinico-pathologic study on iron overloaded patients. Eur J Haematol 42 (1989), 382–388.
68. Pietrangelo, A., Hereditary hemochromatosis—a new look at an old disease. N Engl J Med 350 (2004), 2383–2397.
69. Candell-Riera, J., Lu, L., Seres, L., et al. Cardiac hemochromatosis: beneficial effects of iron removal therapy. An echocardiographic study. Am J Cardiol 52 (1983), 824–829.
70. Rivers, J., Garrahy, P., Robinson, W., Murphy, A., Reversible cardiac dysfunction in hemochromatosis. Am Heart J 113 (1987), 216–217.
71. Brittenham, G.M., Iron-chelating therapy for transfusional iron overload. N Engl J Med 364 (2011), 146–156.
72. Modell, B., Khan, M., Darlison, M., Westwood, M.A., Ingram, D., Pennell, D.J., Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson, 10, 2008, 42.
73. Aessopos, A., Berdoukas, V., Tsironi, M., The heart in transfusion dependent homozygous thalassaemia today—prediction, prevention and management. Eur J Haematol 80 (2008), 93–106.
74. Aessopos, A., Kati, M., Farmakis, D., Polonifi, E., Deftereos, S., Tsironi, M., Intensive chelation therapy in beta-thalassemia and possible adverse cardiac effects of desferrioxamine. Int J Hematol 86 (2007), 212–215.
75. Anderson, L.J., Westwood, M.A., Holden, S., et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol 127 (2004), 348–355.
76. Pennell, D.J., Porter, J.B., Cappellini, M.D., et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood 115 (2010), 2364–2371.
77. Pennell, D.J., Berdoukas, V., Karagiorga, M., et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 107 (2006), 3738–3744.
78. Tanner, M.A., Galanello, R., Dessi, C., et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 115 (2007), 1876–1884.
79. Oudit, G.Y., Trivieri, M.G., Khaper, N., et al. Taurine supplementation reduces oxidative stress and improves cardiovascular function in an iron-overload murine model. Circulation 109 (2004), 1877–1885.
80. Ramos, E., Ruchala, P., Goodnough, J.B., et al. Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis. Blood 120 (2012), 3829–3836.
81. Crielaard, B.J., Lammers, T., Rivella, S., Targeting iron metabolism in drug discovery and delivery. Nat Rev Drug Discov 16 (2017), 400–423.
82. Caines, A.E., Kpodonu, J., Massad, M.G., et al. Cardiac transplantation in patients with iron overload cardiomyopathy. J Heart Lung Transplant 24 (2005), 486–488.
83. Kim, J.S., Judson, M.A., Donnino, R., et al. Cardiac sarcoidosis. Am Heart J 157 (2009), 9–21.
84. Hamzeh, N., Steckman, D.A., Sauer, W.H., Judson, M.A., Pathophysiology and clinical management of cardiac sarcoidosis. Nat Rev Cardiol 12 (2015), 278–288.
85. Birnie, D.H., Nery, P.B., Ha, A.C., Beanlands, R.S., Cardiac sarcoidosis. J Am Coll Cardiol 68 (2016), 411–421.
86. Rybicki, B.A., Major, M., Popovich, J. Jr., Maliarik, M.J., Iannuzzi, M.C., Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol 145 (1997), 234–241.
87. Perry, A., Vuitch, F., Causes of death in patients with sarcoidosis. A morphologic study of 38 autopsies with clinicopathologic correlations. Arch Pathol Lab Med 119 (1995), 167–172.
88. Valeyre, D., Prasse, A., Nunes, H., Uzunhan, Y., Brillet, P.Y., Muller-Quernheim, J., Sarcoidosis. Lancet 383 (2014), 1155–1167.
89. Rybicki, B.A., Iannuzzi, M.C., Frederick, M.M., et al. Familial aggregation of sarcoidosis. A case-control etiologic study of sarcoidosis (ACCESS). Am J Respir Crit Care Med 164 (2001), 2085–2091.
90. Naruse, T.K., Matsuzawa, Y., Ota, M., et al. HLA-DQB1*0601 is primarily associated with the susceptibility to cardiac sarcoidosis. Tissue Antigens 56 (2000), 52–57.
91. Rossman, M.D., Thompson, B., Frederick, M., et al. HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites. Am J Hum Genet 73 (2003), 720–735.
92. Grutters, J.C., Sato, H., Pantelidis, P., et al. Increased frequency of the uncommon tumor necrosis factor-857T allele in British and Dutch patients with sarcoidosis. Am J Respir Crit Care Med 165 (2002), 1119–1124.
93. Valentonyte, R., Hampe, J., Huse, K., et al. Sarcoidosis is associated with a truncating splice site mutation in BTNL2. Nat Genet 37 (2005), 357–364.
94. Baughman, R.P., Teirstein, A.S., Judson, M.A., et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 164 (2001), 1885–1889.
95. Roberts, W.C., Chung, M.S., Ko, J.M., Capehart, J.E., Hall, S.A., Morphologic features of cardiac sarcoidosis in native hearts of patients having cardiac transplantation. Am J Cardiol 113 (2014), 706–712.
96. Murtagh, G., Laffin, L.J., Beshai, J.F., et al. Prognosis of myocardial damage in sarcoidosis patients with preserved left ventricular ejection fraction: risk stratification using cardiovascular magnetic resonance. Circ Cardiovasc Imaging, 9, 2016, e003738.
97. Kandolin, R., Lehtonen, J., Airaksinen, J., et al. Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. Circulation 131 (2015), 624–632.
98. Nery, P.B., Beanlands, R.S., Nair, G.M., et al. Atrioventricular block as the initial manifestation of cardiac sarcoidosis in middle-aged adults. J Cardiovasc Electrophysiol 25 (2014), 875–881.
99. Nery, P.B., Mc Ardle, B.A., Redpath, C.J., et al. Prevalence of cardiac sarcoidosis in patients presenting with monomorphic ventricular tachycardia. Pacing Clin Electrophysiol 37 (2014), 364–374.
100. Kandolin, R., Lehtonen, J., Graner, M., et al. Diagnosing isolated cardiac sarcoidosis. J Intern Med 270 (2011), 461–468.
101. Nelson, J.E., Kirschner, P.A., Teirstein, A.S., Sarcoidosis presenting as heart disease. Sarcoidosis Vasc Diffuse Lung Dis 13 (1996), 178–182.
102. Roberts, W.C., McAllister, H.A. Jr., Ferrans, V.J., Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11). Am J Med 63 (1977), 86–108.
103. Smedema, J.P., Snoep, G., van Kroonenburgh, M.P., et al. Cardiac involvement in patients with pulmonary sarcoidosis assessed at two university medical centers in the Netherlands. Chest 128 (2005), 30–35.
104. Yazaki, Y., Isobe, M., Hiroe, M., et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 88 (2001), 1006–1010.
105. Cooper, L.T. Jr., Giant cell and granulomatous myocarditis. Heart Fail Clin 1 (2005), 431–437.
106. Gasparovic, H., Bueno, R., Rybicki, F.J., et al. Sarcoidosis of the aortic root. J Thorac Cardiovasc Surg 128 (2004), 761–762.
107. Yoshida, Y., Morimoto, S., Hiramitsu, S., Tsuboi, N., Hirayama, H., Itoh, T., Incidence of cardiac sarcoidosis in Japanese patients with high-degree atrioventricular block. Am Heart J 134 (1997), 382–386.
108. Kandolin, R., Lehtonen, J., Kupari, M., Cardiac sarcoidosis and giant cell myocarditis as causes of atrioventricular block in young and middle-aged adults. Circ Arrhythm Electrophysiol 4 (2011), 303–309.
109. Cain, M.A., Metzl, M.D., Patel, A.R., et al. Cardiac sarcoidosis detected by late gadolinium enhancement and prevalence of atrial arrhythmias. Am J Cardiol 113 (2014), 1556–1560.
110. Winters, S.L., Cohen, M., Greenberg, S., et al. Sustained ventricular tachycardia associated with sarcoidosis: assessment of the underlying cardiac anatomy and the prospective utility of programmed ventricular stimulation, drug therapy and an implantable antitachycardia device. J Am Coll Cardiol 18 (1991), 937–943.
111. Koplan, B.A., Soejima, K., Baughman, K., Epstein, L.M., Stevenson, W.G., Refractory ventricular tachycardia secondary to cardiac sarcoid: electrophysiologic characteristics, mapping, and ablation. Heart Rhythm 3 (2006), 924–929.
112. Uusimaa, P., Ylitalo, K., Anttonen, O., et al. Ventricular tachyarrhythmia as a primary presentation of sarcoidosis. Europace 10 (2008), 760–766.
113. Naruse, Y., Sekiguchi, Y., Nogami, A., et al. Systematic treatment approach to ventricular tachycardia in cardiac sarcoidosis. Circ Arrhythm Electrophysiol 7 (2014), 407–413.
114. Crawford, T., Mueller, G., Sarsam, S., et al. Magnetic resonance imaging for identifying patients with cardiac sarcoidosis and preserved or mildly reduced left ventricular function at risk of ventricular arrhythmias. Circ Arrhythm Electrophysiol 7 (2014), 1109–1115.
115. Shafee, M.A., Fukuda, K., Wakayama, Y., et al. Delayed enhancement on cardiac magnetic resonance imaging is a poor prognostic factor in patients with cardiac sarcoidosis. J Cardiol 60 (2012), 448–453.
116. Kandolin, R., Lehtonen, J., Airaksinen, J., et al. Usefulness of cardiac troponins as markers of early treatment response in cardiac sarcoidosis. Am J Cardiol 116 (2015), 960–964.
117. Iannuzzi, M.C., Rybicki, B.A., Teirstein, A.S., Sarcoidosis. N Engl J Med 357 (2007), 2153–2165.
118. Vorselaars, A.D., van Moorsel, C.H., Zanen, P., et al. ACE and sIL-2R correlate with lung function improvement in sarcoidosis during methotrexate therapy. Respir Med 109 (2015), 279–285.
119. Mehta, D., Lubitz, S.A., Frankel, Z., et al. Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest 133 (2008), 1426–1435.
120. Schuller, J.L., Olson, M.D., Zipse, M.M., et al. Electrocardiographic characteristics in patients with pulmonary sarcoidosis indicating cardiac involvement. J Cardiovasc Electrophysiol 22 (2011), 1243–1248.
121. Homsi, M., Alsayed, L., Safadi, B., Mahenthiran, J., Das, M.K., Fragmented QRS complexes on 12-lead ECG: a marker of cardiac sarcoidosis as detected by gadolinium cardiac magnetic resonance imaging. Ann Noninvasive Electrocardiol 14 (2009), 319–326.
122. Nery, P.B., Keren, A., Healey, J., Leug, E., Beanlands, R.S., Birnie, D.H., Isolated cardiac sarcoidosis: establishing the diagnosis with electroanatomic mapping-guided endomyocardial biopsy. Can J Cardiol 29 (2013), 1015.e1–1015.e3.
123. Patel, M.R., Cawley, P.J., Heitner, J.F., et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 120 (2009), 1969–1977.
124. Pizarro, C., Goebel, A., Dabir, D., et al. Cardiovascular magnetic resonance-guided diagnosis of cardiac affection in a Caucasian sarcoidosis population. Sarcoidosis Vasc Diffuse Lung Dis 32 (2016), 325–335.
125. Fahy, G.J., Marwick, T., McCreery, C.J., Quigley, P.J., Maurer, B.J., Doppler echocardiographic detection of left ventricular diastolic dysfunction in patients with pulmonary sarcoidosis. Chest 109 (1996), 62–66.
126. Hyodo, E., Hozumi, T., Takemoto, Y., et al. Early detection of cardiac involvement in patients with sarcoidosis by a non-invasive method with ultrasonic tissue characterisation. Heart 90 (2004), 1275–1280.
127. Skold, C.M., Larsen, F.F., Rasmussen, E., Pehrsson, S.K., Eklund, A.G., Determination of cardiac involvement in sarcoidosis by magnetic resonance imaging and Doppler echocardiography. J Intern Med 252 (2002), 465–471.
128. Joyce, E., Ninaber, M.K., Katsanos, S., et al. Subclinical left ventricular dysfunction by echocardiographic speckle-tracking strain analysis relates to outcome in sarcoidosis. Eur J Heart Fail 17 (2015), 51–62.
129. Smedema, J.P., Snoep, G., van Kroonenburgh, M.P., et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 45 (2005), 1683–1690.
130. Vignaux, O., Cardiac sarcoidosis: spectrum of MRI features. AJR Am J Roentgenol 184 (2005), 249–254.
131. Ichinose, A., Otani, H., Oikawa, M., et al. MRI of cardiac sarcoidosis: basal and subepicardial localization of myocardial lesions and their effect on left ventricular function. AJR Am J Roentgenol 191 (2008), 862–869.
132. Yoshida, A., Ishibashi-Ueda, H., Yamada, N., et al. Direct comparison of the diagnostic capability of cardiac magnetic resonance and endomyocardial biopsy in patients with heart failure. Eur J Heart Fail 15 (2013), 166–175.
133. Vignaux, O., Dhote, R., Duboc, D., et al. Clinical significance of myocardial magnetic resonance abnormalities in patients with sarcoidosis: a 1-year follow-up study. Chest 122 (2002), 1895–1901.
134. Greulich, S., Deluigi, C.C., Gloekler, S., et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. J Am Coll Cardiol Img 6 (2013), 501–511.
135. Ise, T., Hasegawa, T., Morita, Y., et al. Extensive late gadolinium enhancement on cardiovascular magnetic resonance predicts adverse outcomes and lack of improvement in LV function after steroid therapy in cardiac sarcoidosis. Heart 100 (2014), 1165–1172.
136. Pellegrino, D., Bonab, A.A., Dragotakes, S.C., Pitman, J.T., Mariani, G., Carter, E.A., Inflammation and infection: imaging properties of 18F-FDG-labeled white blood cells versus 18F-FDG. J Nucl Med 46 (2005), 1522–1530.
137. Ishimaru, S., Tsujino, I., Takei, T., et al. Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J 26 (2005), 1538–1543.
138. Youssef, G., Leung, E., Mylonas, I., et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med 53 (2012), 241–248.
139. Yamagishi, H., Shirai, N., Takagi, M., et al. Identification of cardiac sarcoidosis with (13)N-NH(3)/(18)F-FDG PET. J Nucl Med 44 (2003), 1030–1036.
140. Okumura, W., Iwasaki, T., Toyama, T., et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 45 (2004), 1989–1998.
141. Tadamura, E., Yamamuro, M., Kubo, S., et al. Images in cardiovascular medicine. Multimodality imaging of cardiac sarcoidosis before and after steroid therapy. Circulation 113 (2006), e771–e773.
142. Liang, J.J., Hebl, V.B., DeSimone, C.V., et al. Electrogram guidance: a method to increase the precision and diagnostic yield of endomyocardial biopsy for suspected cardiac sarcoidosis and myocarditis. J Am Coll Cardiol HF 2 (2014), 466–473.
143. Leone, O., Veinot, J.P., Angelini, A., et al. 2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc Pathol 21 (2012), 245–274.
144. Hamzeh, N.Y., Wamboldt, F.S., Weinberger, H.D., Management of cardiac sarcoidosis in the United States: a Delphi study. Chest 141 (2012), 154–162.
145. Yodogawa, K., Seino, Y., Shiomura, R., et al. Recovery of atrioventricular block following steroid therapy in patients with cardiac sarcoidosis. J Cardiol 62 (2013), 320–325.
146. Kato, Y., Morimoto, S., Uemura, A., Hiramitsu, S., Ito, T., Hishida, H., Efficacy of corticosteroids in sarcoidosis presenting with atrioventricular block. Sarcoidosis Vasc Diffuse Lung Dis 20 (2003), 133–137.
147. Yodogawa, K., Seino, Y., Ohara, T., Takayama, H., Katoh, T., Mizuno, K., Effect of corticosteroid therapy on ventricular arrhythmias in patients with cardiac sarcoidosis. Ann Noninvasive Electrocardiol 16 (2011), 140–147.
148. Birnie, D.H., Sauer, W.H., Bogun, F., et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 11 (2014), 1305–1323.
149. Sadek, M.M., Yung, D., Birnie, D.H., Beanlands, R.S., Nery, P.B., Corticosteroid therapy for cardiac sarcoidosis: a systematic review. Can J Cardiol 29 (2013), 1034–1041.
150. Chiu, C.Z., Nakatani, S., Zhang, G., et al. Prevention of left ventricular remodeling by long-term corticosteroid therapy in patients with cardiac sarcoidosis. Am J Cardiol 95 (2005), 143–146.
151. Banba, K., Kusano, K.F., Nakamura, K., et al. Relationship between arrhythmogenesis and disease activity in cardiac sarcoidosis. Heart Rhythm 4 (2007), 1292–1299.
152. Grutters, J.C., van den Bosch, J.M., Corticosteroid treatment in sarcoidosis. Eur Respir J 28 (2006), 627–636.
153. Nagai, S., Yokomatsu, T., Tanizawa, K., et al. Treatment with methotrexate and low-dose corticosteroids in sarcoidosis patients with cardiac lesions. Intern Med, 53, 2014, 2761.
154. Hamzeh, N., Voelker, A., Forssen, A., et al. Efficacy of mycophenolate mofetil in sarcoidosis. Respir Med 108 (2014), 1663–1669.
155. Muller-Quernheim, J., Kienast, K., Held, M., Pfeifer, S., Costabel, U., Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J 14 (1999), 1117–1122.
156. Demeter, S.L., Myocardial sarcoidosis unresponsive to steroids. Treatment with cyclophosphamide. Chest 94 (1988), 202–203.
157. Judson, M.A., Baughman, R.P., Costabel, U., et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J 31 (2008), 1189–1196.
158. Crommelin, H.A., van der Burg, L.M., Vorselaars, A.D.M., et al. Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab. Respir Med 115 (2016), 72–77.
159. Cinetto, F., Compagno, N., Scarpa, R., Malipiero, G., Agostini, C., Rituximab in refractory sarcoidosis: a single centre experience. Clin Mol Allergy, 13, 2015, 19.
160. Epstein, A.E., DiMarco, J.P., Ellenbogen, K.A., et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 61 (2013), e6–e75.
161. Mehta, D., Mori, N., Goldbarg, S.H., Lubitz, S., Wisnivesky, J.P., Teirstein, A., Primary prevention of sudden cardiac death in silent cardiac sarcoidosis: role of programmed ventricular stimulation. Circ Arrhythm Electrophysiol 4 (2011), 43–48.
162. Schuller, J.L., Zipse, M., Crawford, T., et al. Implantable cardioverter defibrillator therapy in patients with cardiac sarcoidosis. J Cardiovasc Electrophysiol 23 (2012), 925–929.
163. Kron, J., Sauer, W., Schuller, J., et al. Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis. Europace 15 (2013), 347–354.
164. Kumar, S., Barbhaiya, C., Nagashima, K., et al. Ventricular tachycardia in cardiac sarcoidosis: characterization of ventricular substrate and outcomes of catheter ablation. Circ Arrhythm Electrophysiol 8 (2015), 87–93.
165. Perkel, D., Czer, L.S., Morrissey, R.P., et al. Heart transplantation for end-stage heart failure due to cardiac sarcoidosis. Transplant Proc 45 (2013), 2384–2386.
166. Zaidi, A.R., Zaidi, A., Vaitkus, P.T., Outcome of heart transplantation in patients with sarcoid cardiomyopathy. J Heart Lung Transplant 26 (2007), 714–717.
167. Yager, J.E., Hernandez, A.F., Steenbergen, C., et al. Recurrence of cardiac sarcoidosis in a heart transplant recipient. J Heart Lung Transplant 24 (2005), 1988–1990.
168. Zhuang, X.F., Yang, Y.M., Sun, X.L., Liao, Z.K., Huang, J., Late onset radiation-induced constrictive pericarditis and cardiomyopathy after radiotherapy: a case report. Medicine (Baltimore), 96, 2017, e5932.
169. Darby, S.C., Cutter, D.J., Boerma, M., et al. Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys 76 (2010), 656–665.
170. Andratschke, N., Maurer, J., Molls, M., Trott, K.R., Late radiation-induced heart disease after radiotherapy. Clinical importance, radiobiological mechanisms and strategies of prevention. Radiother Oncol 100 (2011), 160–166.
171. Clarke, M., Collins, R., Darby, S., et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366 (2005), 2087–2106.
172. McGale, P., Darby, S.C., Hall, P., et al. Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. Radiother Oncol 100 (2011), 167–175.
173. Saiki, H., Petersen, I.A., Scott, C.G., et al. Risk of heart failure with preserved ejection fraction in older women after contemporary radiotherapy for breast cancer. Circulation 135 (2017), 1388–1396.
174. Chello, M., Mastroroberto, P., Romano, R., Zofrea, S., Bevacqua, I., Marchese, A.R., Changes in the proportion of types I and III collagen in the left ventricular wall of patients with post-irradiative pericarditis. Cardiovasc Surg 4 (1996), 222–226.
175. Prosnitz, R.G., Hubbs, J.L., Evans, E.S., et al. Prospective assessment of radiotherapy-associated cardiac toxicity in breast cancer patients: analysis of data 3 to 6 years after treatment. Cancer 110 (2007), 1840–1850.
176. Heidenreich, P.A., Hancock, S.L., Lee, B.K., Mariscal, C.S., Schnittger, I., Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol 42 (2003), 743–749.
177. Erven, K., Florian, A., Slagmolen, P., et al. Subclinical cardiotoxicity detected by strain rate imaging up to 14 months after breast radiation therapy. Int J Radiat Oncol Biol Phys 85 (2013), 1172–1178.
178. Adams, M.J., Lipsitz, S.R., Colan, S.D., et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 22 (2004), 3139–3148.
179. Lancellotti, P., Nkomo, V.T., Badano, L.P., et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging 14 (2013), 721–740.
180. Zamorano, J.L., Lancellotti, P., Rodriguez Munoz, D., et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for Cancer Treatments and Cardiovascular Toxicity of the European Society of Cardiology (ESC). Eur J Heart Fail 19 (2017), 9–42.
181. Saxena, P., Joyce, L.D., Daly, R.C., et al. Cardiac transplantation for radiation-induced cardiomyopathy: the Mayo Clinic experience. Ann Thorac Surg 98 (2014), 2115–2121.
182. Al-Kindi, S.G., Oliveira, G.H., Heart transplantation outcomes in radiation-induced restrictive cardiomyopathy. J Card Fail 22 (2016), 475–478.